User login
Patiromer, an orally administered potassium-binding polymer, significantly decreased serum potassium in adults who had diabetic kidney disease with hyperkalemia in a phase II study funded by and conducted with the manufacturer.
Patiromer consists of tiny, smooth beads in a liquid suspension and works by binding potassium throughout the GI tract, allowing it to be excreted in the feces. After preliminary studies demonstrated the agent’s usefulness in reducing hyperkalemia for up to 12 weeks in high-risk patients, researchers performed this open-label, uncontrolled trial to determine optimal dosing and to assess its longer-term safety. The findings were reported online July 14 in JAMA.
All four doses of patiromer studied significantly reduced serum potassium, beginning within 48 hours of the initial dose and continuing through all 52 weeks of treatment. The proportion of patients whose potassium levels reached target range at all scheduled visits ranged from 83% to 93% in those who had mild hyperkalemia at baseline and from 77% to 95% in those who had moderate hyperkalemia at baseline. Hyperkalemia quickly reappeared when patiromer treatment ended, reverting to baseline levels, wrote Dr. George L. Bakris of the ASH Comprehensive Hypertension Center, division of endocrinology, diabetes, and metabolism, University of Chicago, and his associates.
Study participants were 222 white patients with mild and 84 with moderate hyperkalemia (mean age, 66 years). All had type 2 diabetes and hypertension, and approximately one-third had heart failure; 65% had stage 3 and 22% had stage 4 chronic kidney disease (CKD), All were taking an ACE inhibitor, an angiotensin II receptor blocker, or both, with or without spironolactone. At 48 medical centers in five European countries, they were randomly assigned to receive one of four doses of patiromer that could be titrated up or down as needed for 4 weeks. Patients then entered an 8-week treatment phase, after which they continued maintenance therapy for a further 40 weeks (JAMA 2015 July 14 [doi:10.1001/jama.2015.7446]).
The optimal doses of patiromer were found to be the two lowest doses assessed in this study, 8.4 g daily and 16.8 g daily, which significantly decreased serum potassium without provoking hypokalemia. These doses will now be tested in a phase III study.
The most frequent treatment-related adverse events in the phase II study were nonsevere hypomagnesemia (7.2%), constipation (4.6%), and diarrhea (2.7%). A total of 28 patients (9.2%) developed at least one adverse event prompting them to discontinue patiromer, including worsening of CKD (which was considered unrelated to treatment), hypokalemia (5 patients), and one hypertensive crisis (also unrelated to treatment). No dose-related edema was noted, and there were no clinically relevant changes in serum calcium or phosphate levels.
The findings of Bakris et al. have the potential to fundamentally change the current treatment approach for hyperkalemia.
Relypsa, the manufacturer of patiromer, filed a New Drug Application with the Food and Drug Administration, and the agent will likely be approved for use in the United States by the end of October. The FDA should consider mandating a sizable postmarketing trial and safety surveillance program to clearly establish the agent’s safety and effectiveness for the hard endpoints that patients care about: halting the progression of chronic kidney disease and thus deferring dialysis, and improving heart failure. Otherwise the manufacturer may not be motivated to conduct such crucial trials, especially if it could instead spend those dollars on marketing and company-directed contract research.
Wolfgang C. Winkelmayer, M.D., Sc.D., is in the nephrology section at Baylor University, Houston, and is an associate editor at JAMA. He reported serving as an adviser or consultant to Amgen, AstraZeneca, Bayer, Keryx, Medgenics, Medtronic, Mitsubishi Tanabe, and Rockwell Pharma. Dr. Winkelmayer made these remarks in an editorial accompanying Dr. Bakris’ report (JAMA 2015 July 14;314:129-30).
The findings of Bakris et al. have the potential to fundamentally change the current treatment approach for hyperkalemia.
Relypsa, the manufacturer of patiromer, filed a New Drug Application with the Food and Drug Administration, and the agent will likely be approved for use in the United States by the end of October. The FDA should consider mandating a sizable postmarketing trial and safety surveillance program to clearly establish the agent’s safety and effectiveness for the hard endpoints that patients care about: halting the progression of chronic kidney disease and thus deferring dialysis, and improving heart failure. Otherwise the manufacturer may not be motivated to conduct such crucial trials, especially if it could instead spend those dollars on marketing and company-directed contract research.
Wolfgang C. Winkelmayer, M.D., Sc.D., is in the nephrology section at Baylor University, Houston, and is an associate editor at JAMA. He reported serving as an adviser or consultant to Amgen, AstraZeneca, Bayer, Keryx, Medgenics, Medtronic, Mitsubishi Tanabe, and Rockwell Pharma. Dr. Winkelmayer made these remarks in an editorial accompanying Dr. Bakris’ report (JAMA 2015 July 14;314:129-30).
The findings of Bakris et al. have the potential to fundamentally change the current treatment approach for hyperkalemia.
Relypsa, the manufacturer of patiromer, filed a New Drug Application with the Food and Drug Administration, and the agent will likely be approved for use in the United States by the end of October. The FDA should consider mandating a sizable postmarketing trial and safety surveillance program to clearly establish the agent’s safety and effectiveness for the hard endpoints that patients care about: halting the progression of chronic kidney disease and thus deferring dialysis, and improving heart failure. Otherwise the manufacturer may not be motivated to conduct such crucial trials, especially if it could instead spend those dollars on marketing and company-directed contract research.
Wolfgang C. Winkelmayer, M.D., Sc.D., is in the nephrology section at Baylor University, Houston, and is an associate editor at JAMA. He reported serving as an adviser or consultant to Amgen, AstraZeneca, Bayer, Keryx, Medgenics, Medtronic, Mitsubishi Tanabe, and Rockwell Pharma. Dr. Winkelmayer made these remarks in an editorial accompanying Dr. Bakris’ report (JAMA 2015 July 14;314:129-30).
Patiromer, an orally administered potassium-binding polymer, significantly decreased serum potassium in adults who had diabetic kidney disease with hyperkalemia in a phase II study funded by and conducted with the manufacturer.
Patiromer consists of tiny, smooth beads in a liquid suspension and works by binding potassium throughout the GI tract, allowing it to be excreted in the feces. After preliminary studies demonstrated the agent’s usefulness in reducing hyperkalemia for up to 12 weeks in high-risk patients, researchers performed this open-label, uncontrolled trial to determine optimal dosing and to assess its longer-term safety. The findings were reported online July 14 in JAMA.
All four doses of patiromer studied significantly reduced serum potassium, beginning within 48 hours of the initial dose and continuing through all 52 weeks of treatment. The proportion of patients whose potassium levels reached target range at all scheduled visits ranged from 83% to 93% in those who had mild hyperkalemia at baseline and from 77% to 95% in those who had moderate hyperkalemia at baseline. Hyperkalemia quickly reappeared when patiromer treatment ended, reverting to baseline levels, wrote Dr. George L. Bakris of the ASH Comprehensive Hypertension Center, division of endocrinology, diabetes, and metabolism, University of Chicago, and his associates.
Study participants were 222 white patients with mild and 84 with moderate hyperkalemia (mean age, 66 years). All had type 2 diabetes and hypertension, and approximately one-third had heart failure; 65% had stage 3 and 22% had stage 4 chronic kidney disease (CKD), All were taking an ACE inhibitor, an angiotensin II receptor blocker, or both, with or without spironolactone. At 48 medical centers in five European countries, they were randomly assigned to receive one of four doses of patiromer that could be titrated up or down as needed for 4 weeks. Patients then entered an 8-week treatment phase, after which they continued maintenance therapy for a further 40 weeks (JAMA 2015 July 14 [doi:10.1001/jama.2015.7446]).
The optimal doses of patiromer were found to be the two lowest doses assessed in this study, 8.4 g daily and 16.8 g daily, which significantly decreased serum potassium without provoking hypokalemia. These doses will now be tested in a phase III study.
The most frequent treatment-related adverse events in the phase II study were nonsevere hypomagnesemia (7.2%), constipation (4.6%), and diarrhea (2.7%). A total of 28 patients (9.2%) developed at least one adverse event prompting them to discontinue patiromer, including worsening of CKD (which was considered unrelated to treatment), hypokalemia (5 patients), and one hypertensive crisis (also unrelated to treatment). No dose-related edema was noted, and there were no clinically relevant changes in serum calcium or phosphate levels.
Patiromer, an orally administered potassium-binding polymer, significantly decreased serum potassium in adults who had diabetic kidney disease with hyperkalemia in a phase II study funded by and conducted with the manufacturer.
Patiromer consists of tiny, smooth beads in a liquid suspension and works by binding potassium throughout the GI tract, allowing it to be excreted in the feces. After preliminary studies demonstrated the agent’s usefulness in reducing hyperkalemia for up to 12 weeks in high-risk patients, researchers performed this open-label, uncontrolled trial to determine optimal dosing and to assess its longer-term safety. The findings were reported online July 14 in JAMA.
All four doses of patiromer studied significantly reduced serum potassium, beginning within 48 hours of the initial dose and continuing through all 52 weeks of treatment. The proportion of patients whose potassium levels reached target range at all scheduled visits ranged from 83% to 93% in those who had mild hyperkalemia at baseline and from 77% to 95% in those who had moderate hyperkalemia at baseline. Hyperkalemia quickly reappeared when patiromer treatment ended, reverting to baseline levels, wrote Dr. George L. Bakris of the ASH Comprehensive Hypertension Center, division of endocrinology, diabetes, and metabolism, University of Chicago, and his associates.
Study participants were 222 white patients with mild and 84 with moderate hyperkalemia (mean age, 66 years). All had type 2 diabetes and hypertension, and approximately one-third had heart failure; 65% had stage 3 and 22% had stage 4 chronic kidney disease (CKD), All were taking an ACE inhibitor, an angiotensin II receptor blocker, or both, with or without spironolactone. At 48 medical centers in five European countries, they were randomly assigned to receive one of four doses of patiromer that could be titrated up or down as needed for 4 weeks. Patients then entered an 8-week treatment phase, after which they continued maintenance therapy for a further 40 weeks (JAMA 2015 July 14 [doi:10.1001/jama.2015.7446]).
The optimal doses of patiromer were found to be the two lowest doses assessed in this study, 8.4 g daily and 16.8 g daily, which significantly decreased serum potassium without provoking hypokalemia. These doses will now be tested in a phase III study.
The most frequent treatment-related adverse events in the phase II study were nonsevere hypomagnesemia (7.2%), constipation (4.6%), and diarrhea (2.7%). A total of 28 patients (9.2%) developed at least one adverse event prompting them to discontinue patiromer, including worsening of CKD (which was considered unrelated to treatment), hypokalemia (5 patients), and one hypertensive crisis (also unrelated to treatment). No dose-related edema was noted, and there were no clinically relevant changes in serum calcium or phosphate levels.
FROM JAMA
Key clinical point: The oral potassium-binding polymer patiromer decreased serum potassium in patients who had diabetic kidney disease with hyperkalemia.
Major finding: The proportion of patients whose potassium levels remained within target range throughout 1 year of treatment was 83%-93% in those who had mild hyperkalemia at baseline and 77%-95% in those who had moderate hyperkalemia at baseline.
Data source: A multicenter open-label, noncontrolled phase II, randomized trial involving 306 adults with diabetic kidney disease and mild to moderate hyperkalemia treated for 1 year.
Disclosures: This study was funded by Relypsa, maker of patiromer. Relypsa also was involved in designing and conducting the study; collecting, analyzing, and interpreting the data; and preparing the manuscript. Dr. Bakris reported receiving personal fees from AbbVie, Takeda. Medtronic, Relypsa, Janssen, Daiichi-Sankyo, Novartis, and Bayer, as well as grants from Takeda. His associates reported ties to numerous industry sources.